UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Drug design, development and therapy, 2019-03, Vol.13, p.949-964

2019

Link zum Volltext

Verfügbarkeit prüfen

Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction

Circulation. Heart failure, 2016-11, Vol.9 (11)

2016

Link zum Volltext

Verfügbarkeit prüfen

Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis

Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8168-8188

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats

European journal of pharmacology, 2021-11, Vol.910, p.174445, Article 174445

2021

Link zum Volltext

Verfügbarkeit prüfen

The potential benefit of endothelin receptor antagonists' therapy in idiopathic pulmonary fibrosis: A meta-analysis of results from randomized controlled trials

Medicine (Baltimore), 2022-10, Vol.101 (40), p.e29981-e29981

2022

Link zum Volltext

Verfügbarkeit prüfen

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Current drug metabolism, 2021-01, Vol.22 (5), p.399

2021

Link zum Volltext

Verfügbarkeit prüfen

Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition

Pediatric nephrology (Berlin, West), 2021-04, Vol.36 (4), p.763-775

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

Expert opinion on drug metabolism & toxicology, 2015-03, Vol.11 (3), p.437-449

2015

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of alkylsulfonyl and substituted benzenesulfonyl curcumin mimics as dual antagonist of L-type Ca(2+) channel and endothelin A/B2 receptor

Bioorganic & medicinal chemistry, 2015-10, Vol.23 (20), p.6673-6682

2015

Link zum Volltext

Verfügbarkeit prüfen

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

Diabetes, obesity & metabolism, 2018-08, Vol.20 (8), p.2019-2022

2018

Link zum Volltext

Verfügbarkeit prüfen

Endothelin receptor antagonists in clinical research — Lessons learned from preclinical and clinical kidney studies

Life sciences (1973), 2014-11, Vol.118 (2), p.141-148

2014

Link zum Volltext

Verfügbarkeit prüfen

Topical application of endothelin receptor a antagonist attenuates imiquimod-induced psoriasiform skin inflammation

Scientific reports, 2020-06, Vol.10 (1), p.9510, Article 9510

2020

Link zum Volltext

Verfügbarkeit prüfen

Endothelin Receptor Antagonists in Kidney Disease

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3427

2023

Link zum Volltext

Verfügbarkeit prüfen

Endothelin and diabetic complications: a brain-centric view

Physiological research, 2018-01, Vol.67 (Suppl 1), p.S83-S94

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects

Journal of clinical pharmacology, 2017-08, Vol.57 (8), p.997-1004

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis

Journal of clinical pharmacy and therapeutics, 2022-02, Vol.47 (2), p.146-156

2022

Link zum Volltext

Verfügbarkeit prüfen

Macitentan: First Global Approval

Drugs (New York, N.Y.), 2014, Vol.74 (1), p.127-133

2014

Link zum Volltext

Verfügbarkeit prüfen

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects

British journal of clinical pharmacology, 2014-11, Vol.78 (5), p.1035-1042

2014

Link zum Volltext

Verfügbarkeit prüfen

Serious Liver Injury Associated with Macitentan: A Case Report

Pharmacotherapy, 2018-02, Vol.38 (2), p.e22-e24

2018

Link zum Volltext

Verfügbarkeit prüfen

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects

Clinical pharmacology in drug development, 2021-07, Vol.10 (7), p.718-725

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats

Journal of cardiovascular pharmacology, 2014-11, Vol.64 (5), p.473-480

2014

Link zum Volltext

Verfügbarkeit prüfen

Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease

Kidney international, 2014-04, Vol.85 (4), p.833-844

2014

Link zum Volltext

Verfügbarkeit prüfen

Endothelin receptor antagonism during preeclampsia: a matter of timing?

Clinical science (1979), 2019-06, Vol.133 (12), p.1341

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Life sciences (1973), 2014-11, Vol.118 (2), p.333-339

2014

Link zum Volltext

Verfügbarkeit prüfen

Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats

Experimental eye research, 2018-11, Vol.176, p.1-9

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 6.300

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.904)
Mit Volltextzugriff
(5.312)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(4.854)
Life Sciences & Biomedicine
(4.778)
Animals
(3.940)
Endothelin Receptor Antagonists
(3.498)
Male
(2.957)
Humans
(2.788)
Rats
(2.195)
Biological And Medical Sciences
(2.140)
Medical Sciences
(1.536)
Pharmacology & Pharmacy
(1.472)
Endothelin
(1.387)
Cardiovascular System & Cardiology
(1.341)
Female
(1.315)
Peptides, Cyclic - Pharmacology
(1.028)
Cardiac & Cardiovascular Systems
(961)
Receptor, Endothelin A
(958)
Rats, Sprague-Dawley
(953)
Endothelin A Receptor Antagonists
(860)
Endothelin-1 - Pharmacology
(777)
Endothelin-1
(765)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta E-Journals
(3.538)
Journals@Ovid Complete
(3.241)
EZB Electronic Journals Library
(3.150)
IngentaConnect Journals
(1.709)
Elsevier ScienceDirect Journals Complete
(1.381)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.116)
Single Journals
(985)
Wiley Blackwell Single Titles
(865)
Wiley Online Library
(698)
Springer Nature - Complete Springer Journals
(463)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(318)
Oxford Journals Online Current
(280)
Oxford Journals 2020 Medicine
(232)
Taylor & Francis Current Content Access
(202)
Taylor & Francis Journals Complete
(188)
Nature
(121)
SAGE Complete
(114)
Nexis Uni
(99)
Psychology & Behavioral Sciences Collection
(55)
Thieme Connect Journals
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction

Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis

Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats

The potential benefit of endothelin receptor antagonists' therapy in idiopathic pulmonary fibrosis: A meta-analysis of results from randomized controlled trials

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition

Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

Synthesis of alkylsulfonyl and substituted benzenesulfonyl curcumin mimics as dual antagonist of L-type Ca(2+) channel and endothelin A/B2 receptor

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

Endothelin receptor antagonists in clinical research — Lessons learned from preclinical and clinical kidney studies

Topical application of endothelin receptor a antagonist attenuates imiquimod-induced psoriasiform skin inflammation

Endothelin Receptor Antagonists in Kidney Disease

Endothelin and diabetic complications: a brain-centric view

Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects

Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis

Macitentan: First Global Approval

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects

Serious Liver Injury Associated with Macitentan: A Case Report

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects

Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats

Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease

Endothelin receptor antagonism during preeclampsia: a matter of timing?

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats

Suchergebnisse filtern